Welcome to our dedicated page for Proto Labs SEC filings (Ticker: PRLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Proto Labs, Inc. filings document the regulatory record for an NYSE-listed digital manufacturing company that produces custom parts for prototyping, testing, bridge production, short-run production, and end-use applications. Its SEC disclosures cover operating results, revenue by service activity, non-GAAP measures, cash-flow commentary, and business updates related to CNC machining, digital platforms, and manufacturing capacity.
PRLB filings also include Form 8-K material-event reports for earnings releases and executive leadership changes, amendments to previously furnished results information, and proxy materials covering board matters, executive compensation, equity awards, shareholder voting items, and governance. The company’s filings identify its common stock under the PRLB ticker on the New York Stock Exchange.
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported equity compensation transactions on February 25, 2026. He received a grant of 4,404 employee stock options and a separate award of 2,415 shares of common stock, both recorded at a price of $0.00 as they are compensation grants.
The filing also shows a disposition of 531 shares of common stock at $62.63 per share classified as a tax-withholding transaction, used to satisfy tax obligations related to the award. After these transactions, his direct common stock holdings totaled 27,186 shares. Footnotes state that 25% of the restricted stock units vest on February 25, 2027, with additional 25% portions vesting on each February 25th thereafter until fully vested.
Proto Labs Inc Chief Technology & AI Officer Marc Kermisch reported equity awards on February 25, 2026. He acquired an employee stock option for 5,095 shares at an exercise price of $0.00 per share and a grant of 2,795 shares of common stock.
The filing explains that the common stock reflects restricted stock units, with 25% of the shares scheduled to vest on February 25, 2027, and additional 25% tranches vesting on each February 25 thereafter until fully vested. Following the award, he directly owned 6,513 shares of common stock.
Proto Labs, Inc. is a Minnesota-based digital manufacturer that produces custom prototype and low-volume production parts through injection molding, CNC machining, 3D printing, and sheet metal fabrication, fulfilling work in its own factories and via the Protolabs Network of global manufacturing partners.
The company emphasizes speed, e‑commerce ordering and automated quoting, claiming over 700 million parts produced for more than 300,000 customers, including a large share of Fortune 100 companies. As of June 30, 2025, non‑affiliate market value was about $0.9 billion, with 23,775,160 common shares outstanding as of February 17, 2026. Its strategy centers on four pillars: elevating customer experience, accelerating innovation, expanding production use cases, and driving operational efficiency.
Proto Labs highlights AI use in pricing, sourcing, quality inspection and toolpath verification, and holds 60 issued U.S. patents plus additional applications and trademarks. The 10‑K details environmental and social initiatives, including solar power at a major facility, STEM grants, and extensive employee training, as well as extensive risk factors covering competition, technology change, cybersecurity, AI governance, global operations, and regulatory and market volatility.
Proto Labs Inc Chief Financial Officer Daniel Schumacher reported a Form 4 transaction involving company common stock. On February 13, 2026, he disposed of 1,267 shares of Proto Labs common stock at $67.52 per share to satisfy tax obligations by delivering shares. After this tax-withholding disposition, he directly owned 42,704 common shares of Proto Labs.
Proto Labs Inc Chief Operations Officer Michael R. Kenison reported two transactions in company common stock. On February 17, 2026, he sold 5,000 shares in an open-market transaction at a weighted average price of $66.463 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 25,302 shares directly held afterward.
Earlier, on February 13, 2026, he disposed of 1,540 shares at $67.52 per share to cover tax obligations through a stock withholding transaction, after which his direct holdings were 30,302 shares. The open-market sale prices ranged from $66.01 to $66.87 per share.
Disciplined Growth Investors, Inc. filed an amended Schedule 13G reporting its ownership in Proto Labs Inc12/31/2025, it beneficially owned 2,673,729 shares of Proto Labs common stock, representing 11.3% of the class.
The firm has sole voting power over 2,398,250 shares and sole dispositive power over 2,673,729 shares, with no shared voting or dispositive power. It certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Proto Labs.
Proto Labs Chief Operations Officer Michael R. Kenison reported a tax-related share withholding transaction. On 02/10/2026, 2,684 shares of common stock were disposed of at $53.18 per share to cover tax obligations, leaving him with 31,842 shares of Proto Labs common stock held directly.
Proto Labs Inc. Chief Financial Officer Daniel Schumacher reported routine equity compensation activity. On February 11, 2026, he exercised 3,135 employee stock options at an exercise price of $33.84 per share, receiving the same number of common shares and holding 43,971 shares directly afterward.
On February 10, 2026, 6,809 common shares were withheld at $53.18 per share to satisfy the exercise price or tax liabilities related to equity awards. All transactions are reported as direct ownership, and the option was noted as fully vested.
Proto Labs Inc. executive stock sale disclosed
Proto Labs Inc. Chief Operations Officer Michael R. Kenison reported selling 2,500 shares of common stock on February 6, 2026 at $60 per share. After this planned trade, he beneficially owns 34,526 shares of Proto Labs common stock.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Mr. Kenison adopted on August 15, 2025, which is designed to allow insiders to sell shares according to predetermined instructions.
This notice states that an insider plans to sell 7,500 shares of common stock of the issuer under Rule 144. The planned sale, through Morgan Stanley Smith Barney, has an aggregate market value of $393,600 based on the filing and is expected around February 6, 2026 on the NYSE. The filing notes that there were 23,678,745 common shares outstanding at the time referenced.
The 7,500 shares to be sold were acquired as restricted stock units from the issuer on May 20, 2020. In the past three months, Rule 10b5-1 sales for Michael Kenison included a prior sale of 3,048 common shares on November 25, 2025 for gross proceeds of $152,930.66.